Quick Info
Status
This study has been completed
Estimated Enrollment
458
Phase
2
Treatment Type
Drug: CK-2127107
Trial Type
Randomized. Parallel Assignment
Sponsor
Primary Investigator
Study Director MD Cytokinetics
Contact Information
Locations
CHUM Research Center, Montréal, H2X 0A9
Carol & Frank Morsani Center Advanced Healthcare University of South Florida, Tampa, 33612
Cedars-Sinai Medical Center, Los Angeles, 90048
Cleveland Clinic, Cleveland, 44195
Duchossois Center for Advanced Medicine, Chicago, 60637
Duke Neurological Disorders Clinic, Durham, 27705
Edmonton Kaye Clinic, Edmonton, T6GT 1Z1
Emory Clinic, Atlanta, 30322
Forbes Norris MDA/ALS Research Center, San Francisco, 94115
Froedtert Memorial Lutheran Hospital, Milwaukee, 53226
Hennepin County Medical Center, Minneapolis, 55415
Henry Ford Health System, Detroit, 48202
Hospital For Special Surgery, New York, 10021
Hospital for Special Care, New Britain, 06053
Houston Methodist Hospital, Houston, 77030
Hôpital de l'Enfant-Jésus, CHU de Québec 1401, 18e Rue, Quebec City, G1J 1Z4
IU Health Neuroscience Center of Excellence, Indianapolis, 46202
Mayo Clinic, Jacksonville, 32224
Mayo Clinic, Rochester, 55905
McMaster University Medical Centre, Hamilton, L8N 3Z5
Michigan Medicine, Ann Arbor, 48109
Montreal Neurological Institute and Hospital, Montreal, H3A 2B4
Neurology Associates, P.C., Lincoln, 68506
Penn State Milton S. Hershey Medical Center, Hershey, 17033
Providence Brain and Spine Institute ALS Center, Portland, 97213
SUNY Upstate Medical University, Syracuse, 13210
Saint Louis University, Department of Neurology, Saint Louis, 63104
St. Joseph's Hosp & Med Center - Barrow Neuro. Cen, Phoenix, 85013
Stanford Hospital and Clinics, Stanford, 94305
Texas Neurology, Dallas, 75214
The Ohio State University Wexner Medical Center, Columbus, 43210
UC Irvine, Orange, 92868
UTHSCSA Medical Arts and Research Center, San Antonio, 78229
University of Calgary, Heritage Medical Research C, Calgary, T2N 4Z6
University of Colorado Hospital Anschutz Outpatien, Aurora, 80045
University of Kansas Medical Center, Kansas City, 66160
University of Vermont Medical Center, Burlington, 05405
University of Virginia Health System, Charlottesville, 22908
University of Washington Medical Center, Seattle
VCU Health - Ambulatory Care Center (ACC), Richmond, 23298
Vanderbilt University Medical Center Clinical Research Center, Nashville, 37232
Wake Forest School of Medicine, Winston-Salem, 27157
Washington University School of Medicine, Saint Louis, 63110
West Virginia University, Dept. of Neurology, Morgantown, 26506
George Washington University Medical Faculty Assoc, Washington DC, 20037
University of Iowa Hospitals and Clinics, Iowa City, 52242
Temple University School of Medicine, Philadelphia, 19140
London Health Sciences Centre University Hospital, London, N6A 5A5
University of Florida, Gainesville, 32610
Oregon Health & Science University, Portland, 97239
Beaumont Hospital, Dublin
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
SVC ≥ 65%
Months Since Onset
Number of months since first symptoms of ALS.
≤ 24 months from diagnosis (not onset)
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
No
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
No
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Yes
Update Notes
Trial complete
4/8/2019
No significant updates
3/11/2019
Recruitment status updated
2/15/2019
Location updated
10/24/2018
Location updated
9/25/2018
Trial details updated
9/10/2018
Location updated
4/2/2018
Trial name updated
4/2/2018
Location updated
3/23/2018
Location updated
3/15/2018
Location updated
3/6/2018
No significant updates
3/1/2018
Location updated
2/20/2018
No significant updates
2/9/2018
Location updated
2/6/2018
Location updated
1/31/2018
Location updated
1/24/2018
Locations updated
1/10/2018
Locations updated
1/3/2018
Locations updated
12/20/2017
Locations updated
12/4/2017
Locations updated
11/27/2017
Locations updated
11/7/2017
Location updated
10/27/2017
10/23/2017
Location updated
10/5/2017
Location updated
9/28/2017
Location updated
9/15/2017
No significant updates
9/6/2017
Recruitment status and location updated
8/1/2017
New trial added
5/22/2017

Other Information

Purpose
The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
Eligibility
18-80 years, all genders, not accepting healthy volunteers
Details
May be referred to as the FORTITUDE-ALS clinical trial. Enrolled participants will be dosed with CK-2127107 150, 300, 450 mg or placebo twice daily (300, 600, 900 mg/day or placebo) for a period of 12 weeks.
ALS Forum
-
×
End of Year Appeal 2019 End of Year Appeal 2019
Join the race to End ALS
Support the advancement of promising treatments to help David and others with ALS.
Support the advancement of promising treatments
to help David and others with ALS.